There is increasing evidence that human herpes viruses and human endogenous retroviruses (HERV) are involved in the aetiology and pathogenesis of multiple sclerosis (MS). In order to acquire the ultimate evidence to confirm such a relationship, it is probably required to use specific antiviral drugs in clinical trials of MS. The results of published antiviral clinical trials in patients with MS are summarized in this review.
| INTRODUCTION
The prevailing hypothesis of the aetiology and pathogenesis of multiple sclerosis (MS) is that it is an immune-mediated deterioration of the central nervous system (CNS), induced by environmental and lifestyle factors in genetically predisposed persons. 1 Infectious agent(s) may be involved in this process, either directly or through autoimmune mechanisms. In particular, human herpes virus and retrovirus infections have been suggested and explored as possible candidates in the search for a cause of MS. 2 However, with the exception of HERV, the association of MS with human retroviruses appears to have been ruled out. 3 In contrast, evidence that human herpes virus infections, in particular Epstein-Barr virus (EBV) 4 and human herpes virus 6 (HHV-6), 5 may have pathogenic roles in MS is accumulating.
Human herpes viruses and HERV are ubiquitous agents in populations where MS is prevalent. In adult members of these populations, the seroprevalence of human herpes viruses (except for human herpes virus 8) is 50%-100%, and HERV comprises part of the genome of all humans. This ubiquity means that the possibility to demonstrate serological or molecular biological evidence of their involvement in MS is limited. It is likely that the only way to conclusively demonstrate the involvement of human herpes viruses or HERV in MS is through controlled clinical trials of antiviral drugs. In this review, we summarize the data from the intriguing but inconclusive published antiviral trials that specifically target herpes viruses or HERV in patients with MS.
| ANTIHERPES VIRUS TREATMENT OF MS
Human herpes viruses are ubiquitous agents possessing features such as neurotrophism and the ability to cause latency, which make them intriguing aetiologic candidates in MS. Currently, there is strong evidence in support of a relationship between EBV and HHV-6 and MS. 4, 5 However, data on the role of other human herpes viruses in the pathogenesis of MS are much weaker. Interestingly, anti-CD 20 monoclonal antibody therapies are highly efficacious in relapse-remitting MS (RRMS). 6, 7 This antibody depletes B cells from circulation, and as EBV is harboured in B cells, the anti-CD 20 treatment effectively eradicates the EBV infection from the host. Although the mechanism of anti-CD 20 in RRMS is considered to be immunomodulatory, the possibility that the effect could be partly due to EBV suppression has not been eliminated.
There are three published randomized and placebo-controlled phase 2 clinical trials (RCT) of antiherpes treatment in patients with MS. One that investigates acyclovir and two that investigate its prodrug valacyclovir. [8] [9] [10] All were conducted 20-30 years ago, before the era when disease-modifying immunomodulatory therapies were established in RRMS. No magnetic resonance imaging (MRI) was included in this study.
Baseline characteristics showed no significant difference between placebo and acyclovir-treated patients. The mean ARR was 1.03 in acyclovir compared with 1.57 in placebo-treated patients, that is a reduction in 34% (P = .083). If patients were grouped in low (0-2), medium (3-5) and high (≥6) relapse rates, the difference between acyclovir and placebo was significant (P = .017). The ARR during a 2-year prior baseline period was compared with that of the study period in patients who had at least 2 years of disease duration prior to randomization ( Figure 1 ). Acyclovir-treated patients (n = 19)
showed a mean ARR reduced by 0.44, while the corresponding placebo group (n = 20) showed a 0.37 higher mean ARR during the study (P = .024). No other significant differences were observed.
Over the 2-year study, the serum antibody titres of HSV-1 and 2
decreased significantly in acyclovir-treated patients but remained unchanged for other human herpes viruses and in CSF.
In another two-centre, randomized, double-blind, placebocontrolled trial, the effect of valacyclovir (1000 mg t.i.d.) was assessed in 70 patients with RRMS. 8 The However, during the pretreatment period (week 0-4), one patient in the valacyclovir and seven in the placebo group had a relapse, which indicated higher disease activity in the placebo group during the pretreatment phase. The primary outcome was not reached, nor did other MRI or clinical end points show any significant differences between the treatment groups. However, in a protocol-planned exploratory analysis, the median number of new lesions was compared between patients with more than one active lesion at baseline. In this high-activity group, valacyclovir-treated patients (n = 17) had 2.0 lesions per scan compared with 6.5 lesions per scan in placebo patients (P = .025), and the proportion of scans with no activity was 28% in the valacyclovir and 5% in the placebo group (P < .001).
In a third 2-year, single-centre RCT, the effect of valacyclovir on disability progression was investigated in patients with MS. 
i.d.)-treated MS patients, the peak acyclovir concentration in serum
increased seven times compared with that obtained with acyclovir (800 mg t.i.d) treatment, and the ID 50 was extended to also include EBV and to partially include cytomegalovirus (CMV) and HHV-6. 13 The acyclovir concentration in CSF was 20% of that found in serum. 13 Consequently, the acyclovir concentration in CSF during valacyclovir (1000 mg t.i.d.) treatment reached ID 50 for HSV 1 and 2, and partially for VZV.
| ANTIVIRAL TREATMENT OF HUMAN ENDOGENOUS RETROVIRUS INFECTION IN MS
In a recent epidemiological study, patients with HIV infection had a significantly lower risk of developing MS than controls. 14 This could be an effect of HIV-induced immunosuppression, but another possibility is that HIV antiretroviral treatment may coincidentally inhibit HERV, which is implicated in MS. HERV genes represent about 8% of the human genome. 15, 16 Recent studies suggest that a member of the HERV family W, the multiple sclerosis-associated retrovirus (MSRV), plays a role in the pathophysiology of MS. 17 In the brains of patients with MS, MSRV envelope protein (Env) is expressed in MS lesions. In two RCTs, one phase I and one phase IIa study, the safety, pharmacokinetic properties, immunogenicity and efficacy of GNbAC1 were investigated. In the phase I study, 33 healthy male controls were randomized to GNbAC1 (n = 23) or placebo (n = 10). 20 GNbAC1 was well tolerated after single intravenous infusions of GNbAC1 between 0.0025 and 6 mg/kg. In the phase IIa study, 10 patients with MS, 1 patient with RRMS and 9 patients with progressive MS were randomized to single intravenous infusions of GNbAC1 at 2 mg/kg, 6 mg/kg or placebo. Afterwards, all patients received 5 doses of 2 or 6 mg/kg GNbAC1 at 4-week intervals, 21 and 8 of them completed a 6-month extension with the same treatment regimen. 22 GNbAC1 was well tolerated, showed dose-linear pharmacokinetics, had an elimination halflife of 27-37 days, and no anti-GNbAC1 antibodies were detected. No relapses occurred, and only one patient had a new lesion on brain MRI during the 6-month study.
Raltegravir, an HIV integrase inhibitor that blocks retroviral replication, was investigated in a phase IIb study. 23 Twenty active RRMS patients were enrolled in a 3-month baseline phase followed by a 3-month treatment phase with raltegravir (400 mg) twice a day. Monthly MRI showed no treatment effect on the number of gadolinium enhancing lesions, which was the primary outcome of the study. There was also no effect on disability or quality of life measures. However, there was a correlation between HERV-W or MSRV Gag Flix B cells and the number of Gd-enhanced lesions (r = −.54; P = .012), but no significant association between EBV shedding and number of new lesions on MRI. 24 Raltegravir had no effect on inflammatory biomarkers and presence of CD 163, a marker of monocytes and macrophages. Three phase II clinical trials of acyclovir or its prodrug valacyclovir have been conducted in patients with MS. [8] [9] [10] Although they did not meet primary end points, there was a strong trend in the data, with a 34% reduction in ARR in acyclovir-treated patients, and subgroup analysis showed a significant reduction in relapse rate in favour of acyclovir treatment. 10 Moreover, in a predefined subgroup analysis, valacyclovir-treated patients with high disease activity at baseline had significant reduction in new lesions compared to a comparable group of placebo-treated patients. 8 Taken together, these results imply that acyclovir-sensitive virus infection may be involved in RRMS and indicate a need for further investigation.
| CONCLUSION
Oral treatment of valacyclovir (1000 mg t.id.) increased the acyclovir concentration in serum and CSF considerably, compared to acyclovir treatment (800 mg t.i.d.). 12, 13 The antiherpes spectrum expanded and can partly reach ID 50 for EBV, CMV and HHV 6. While the role of CMV in MS has been disputed, 25, 26 evidence of the involvement of HHV-6 and EBV in MS is accumulating. 4, 5 A clinical trial including antivirals such as ganciclovir, foscarnet and cidofovir would better ensure inhibition of these herpes viruses.
Two different therapies, one using the monoclonal antibody GNbCA1 21,22,27 and one using raltegravir, an established antiretroviral therapy, 23, 24 have been used in phase II trials of MS. None of these trials showed a significant effect on the primary outcome in patients with MS. However, they were all limited in sample size and were essentially designed to explore the safety and tolerability of the treatment and not clinical efficacy. These attempts constitute the basis for further investigations to reveal whether HERV is involved in the pathogenesis of MS.
